When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people. Five years later, after halting the development of its first licensed product, the Newark, CA-based precision oncology company awaits topline results from a pivotal Phase 3 trial in liposarcoma, which could open the door to a cancer therapy — milademetan — capable of treating as many as half of all known cancer types.